Literature DB >> 2783515

Intracranial oligodendrogliomas: imaging findings in 35 untreated cases.

Y Y Lee1, P Van Tassel.   

Abstract

The radiographic findings in 35 cases of untreated intracranial oligodendrogliomas were reviewed. The mean age of the patients was 34.6 years, and seizure disorder and headache were the most frequent presenting symptoms. Slightly less than two-thirds of the tumors were histologically pure and almost half were low-grade. Most lesions were cerebral and peripheral in location, and the majority were in the frontal lobes. On CT the tumors were usually hypo- or isodense. Contrast enhancement of tumor occurred in nearly half the cases, and was usually mild and poorly defined. Tumor calcification often occurred, and hemorrhage or cystic formation was not infrequent. Occasionally, calvarial erosion was associated with the tumors because of their peripheral location and slow-growing nature. The lesions were usually sharply demarcated and without edema. MR most frequently revealed hypointense lesions on T1-weighted images and abnormal hyperintensity on T2-weighted scans. In regard to grading or purity of oligodendrogliomas, no significant correlations were found except for a suggestion that higher-grade and mixed tumors tend to enhance more often on CT. The radiographic features of oligodendroglioma are quite characteristic but not pathognomic. A high preoperative suspicion might lead to more appropriate tumor management. MR, although less sensitive in detecting tumor calcification, is superior to CT in defining the tumor extent, which is beneficial for surgical and postsurgical radiotherapy planning.

Entities:  

Mesh:

Year:  1989        PMID: 2783515     DOI: 10.2214/ajr.152.2.361

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  31 in total

Review 1.  Brain imaging.

Authors:  R I Grossman
Journal:  AJNR Am J Neuroradiol       Date:  2000-01       Impact factor: 3.825

2.  Detection of intratumoral calcification in oligodendrogliomas by susceptibility-weighted MR imaging.

Authors:  M Zulfiqar; N Dumrongpisutikul; J Intrapiromkul; D M Yousem
Journal:  AJNR Am J Neuroradiol       Date:  2012-01-19       Impact factor: 3.825

Review 3.  Multimodality Brain Tumor Imaging: MR Imaging, PET, and PET/MR Imaging.

Authors:  James R Fink; Mark Muzi; Melinda Peck; Kenneth A Krohn
Journal:  J Nucl Med       Date:  2015-08-20       Impact factor: 10.057

Review 4.  Intra-axial brain tumours.

Authors:  G Wilms; Ph Demaerel; S Sunaert
Journal:  Eur Radiol       Date:  2004-12-31       Impact factor: 5.315

5.  Calcification in high grade gliomas treated with bevacizumab.

Authors:  Deborah T Blumenthal; Orna Aisenstein; Idan Ben-Horin; Dafna Ben Bashat; Moran Artzi; Benjamin W Corn; Andrew A Kanner; Zvi Ram; Felix Bokstein
Journal:  J Neurooncol       Date:  2015-05-05       Impact factor: 4.130

6.  Can tumor contrast enhancement be used as a criterion for differentiating tumor grades of oligodendrogliomas?

Authors:  Matthew L White; Yan Zhang; Patricia Kirby; Timothy C Ryken
Journal:  AJNR Am J Neuroradiol       Date:  2005-04       Impact factor: 3.825

7.  Prognostic significance of CT contrast enhancement within histological subgroups of intracranial glioma.

Authors:  K Lote; T Egeland; B Hager; K Skullerud; H Hirschberg
Journal:  J Neurooncol       Date:  1998-11       Impact factor: 4.130

8.  An uncommon cause of transient neurological dysfunction.

Authors:  Muhammad U Farooq; Archit Bhatt; Howard T Chang
Journal:  Neurohospitalist       Date:  2014-07

9.  Imaging characteristics of oligodendrogliomas that predict grade.

Authors:  L Khalid; M Carone; N Dumrongpisutikul; J Intrapiromkul; D Bonekamp; P B Barker; D M Yousem
Journal:  AJNR Am J Neuroradiol       Date:  2012-01-19       Impact factor: 3.825

Review 10.  Pathology and molecular genetics of oligodendroglial tumors.

Authors:  Christian Hartmann; Wolf Mueller; Andreas von Deimling
Journal:  J Mol Med (Berl)       Date:  2004-10       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.